{"entity":{"id":"nct03944772","kind":"trial","name":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","aka":["ORCHARD"],"tldr":"A phase 2 trial of Osimertinib, Savolitinib, Gefitinib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) is a phase 2 interventional study registered as NCT03944772 by AstraZeneca, with 247 participants enrolled, started 2019-06-25 and due to reach its primary completion in 2025-05-06. Interventions recorded: Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03944772","url":"https://clinicaltrials.gov/study/NCT03944772"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["osimertinib","savolitinib","gefitinib","necitumumab","durvalumab","carboplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct03944772-jco-precis-oncol-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03944772","phase":"2","setting":"A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.","sponsor":"AstraZeneca","started":"2019-06-25","startedType":"actual","enrolled":247,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03944772/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/"},{"id":"necitumumab","kind":"drug","name":"Necitumumab","route":"/drugs/necitumumab/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"paper":[{"id":"paper-nct03944772-jco-precis-oncol-2025","kind":"paper","name":"ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib","route":"/key-papers/paper-nct03944772-jco-precis-oncol-2025/"}]}}